Avalyn Pharma is a clinical-stage biopharmaceutical company that IPO'd roughly fourteen weeks before this report, and the second-quarter print is the first full quarter in which the post-IPO balance sheet, the post-IPO share count, and the running Phase 2b enrollment all show up on the same page. The load-bearing facts are clean. Cash, cash equivalents, and marketable securities stood at $413.5 million at quarter-end, against six months of operating cash use totaling $56.0 million, and management projects the runway out into 2029 - past the company's two named Phase 2 topline readouts. The Phase 2b MIST trial in progressive pulmonary fibrosis completed enrollment in the quarter at 398 patients (over-enrolled from a 375 target) and is on track for a second-half-2027 readout; the Phase 2 AURA trial in idiopathic pulmonary fibrosis is enrolling at 160 patients with a late-2027 readout; and a Phase 1 of the combination candidate AP03 is expected to start by year-end. The GAAP net loss of $28.9 million in the quarter (versus $20.2 million a year ago) is the cost of that clinical velocity. There is no Q2 revenue and the company does not publish a revenue or earnings forecast; the equity is priced on a milestone clock, not an earnings stream. The open question the quarter sets up for the next twelve months is whether the cash buffer the IPO bought can carry the company to a binary MIST readout before dilution becomes the answer to a shorter runway.